碩騰公司 ZTS 深 滬
已收盤 05-08 16:00:00 美东时间
82.83
-4.480
-5.13%
華盛通- 最 高87.58
- 今 開87.315
- 成交量 1718.64万股
- 最 低 81.10
- 昨 收 87.31
- 總市值 348.31亿
- 52周最高 170.17
- 市盈率 靜 13.75
- 換手率 4.09%
- 52周最低 81.10
- 委 比 0.00%
- 總股本 4.21亿
- 歷史最高 241.682
- 量 比 1.91
- 振 幅 7.42%
- 歷史最低 16.311
- 每 手 1
- 風險率 16.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Most healthcare companies report higher Y/Y EPS in strong earnings week
Healthcare companies delivered strong earnings this week, with 18 out of 20 companies beating EPS estimates and 15 topping revenue expectations, as resilient demand across pharmaceuticals, healthcare ...
05-09 23:30
JP Morgan Maintains Overweight on Zoetis, Lowers Price Target to $130
JP Morgan analyst Chris Schott maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $190 to $130.
05-09 02:48
U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson
U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson May 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, McDonald's and McKesson on Friday. HIGHLIGHTS * Applied Materials Inc AMAT.O : Berenb
05-08 15:12
财报速睇 | 硕腾公司 2026财年Q1营收22.62亿美元，同比增长2.9%；归母净利润6.01亿美元，同比下滑0.2%
华盛资讯5月8日讯，硕腾公司公布2026财年Q1业绩，公司Q1营收22.62亿美元，同比增长2.9%，归母净利润6.01亿美元，同比下滑0.2%。
05-08 07:09
财报速睇 | 硕腾公司 2026财年Q1营收22.62亿美元，同比增长2.9%；归母净利润6.01亿美元，同比下滑0.2%
华盛资讯5月7日讯，硕腾公司公布2026财年Q1业绩，公司Q1营收22.62亿美元，同比增长2.9%，归母净利润6.01亿美元，同比下滑0.2%。
05-07 20:57
Zoetis cuts 2026 outlook as U.S. sales fall in Q1
Shares of Zoetis (ZTS) fell ~13% in the premarket on Thursday after the veterinary product maker lowered its full-year outlook, citing a challenging first quarter marked by a decline in its U.S. reven...
05-07 20:24
Zoetis shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY26 guidance.
Zoetis shares are trading lower after the company reported worse-than-expected ...
05-07 19:27
美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元
04-29 10:28
UBS Maintains Neutral on Zoetis, Lowers Price Target to $130
UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target from $136 to $130.
04-28 22:27
